Home
Conditions
Refractory Multiple Myeloma

Clinical trial condition

Refractory Multiple Myeloma

Explore clinical trials studying Refractory Multiple Myeloma. Study availability and eligibility vary by location and protocol.

155 public trials 23 recruiting studies

Refine in advanced search Browse all conditions

Refractory Multiple Myeloma trial results

Active, not recruiting

Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)

NCT06308822

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +19 more
Locations: ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States

View Trial Details

Active, not recruiting

Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)

NCT06303167

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +22 more
Locations: ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States

View Trial Details

Active, not recruiting

A Clinical Study to Evaluate the Effects of RO7875913 in Healthy Participants and of RO7875913 With Cevostamab in Participnats With With Relapsed/Refractory Multiple Myeloma

NCT07342114

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Healthy Volunteers, +15 more
Locations: New Zealand Clinical Research - Christchurch Christchurch, Canterbury, New Zealand

View Trial Details

Active, not recruiting

Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)

NCT04439136

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +22 more
Locations: ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States

View Trial Details

Active, not recruiting

Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E)

NCT06390852

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +19 more
Locations: ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States

View Trial Details

Active, not recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

NCT02465060

Conditions: Adenocarcinoma, Adnexal Diseases, Advanced Lymphoma, +138 more
Locations: University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States

Thomas Hospital Fairhope, Alabama, United States

Mobile Infirmary Medical Center Mobile, Alabama, United States

University of South Alabama Mitchell Cancer Institute Mobile, Alabama, United States

View all 1410 locations

View Trial Details

Active, not recruiting

Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

NCT00114101

Conditions: Blood Protein Disorders, Cardiovascular Diseases, DS Stage I Multiple Myeloma, +19 more
Locations: Mayo Clinic in Arizona Scottsdale, Arizona, United States

City of Hope Comprehensive Cancer Center Duarte, California, United States

University of California Davis Comprehensive Cancer Center Sacramento, California, United States

UC San Diego Medical Center - Hillcrest San Diego, California, United States

View all 140 locations

View Trial Details

Active, not recruiting

Ixazomib-pomalidomide-dexamethasone as Second or Third-line Combination Treatment for Patients With Relapsed and Refractory Multiple Myeloma Previously Treated With Daratumumab, Lenalidomide and Bortezomib

NCT04790474

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations: Emek Medical Center Afula, Israel

Rambam Medical Center Haifa, Israel

Hadassah Ein-Kerem Medical Center Jerusalem, Israel

Shearei Zedek Medical Center Jerusalem, Israel

View Trial Details

Active, not recruiting

TriPRIL CAR T Cells in Multiple Myeloma

NCT05020444

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations: Massachusetts General Hospital Cancer Center Boston, Massachusetts, United States

View Trial Details

Active, not recruiting

Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)

NCT04439227

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +22 more
Locations: ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States

View Trial Details

Refractory Multiple Myeloma

Refractory Multiple Myeloma trial results

Related conditions